Confidently create your clinically driven GPO contracts with timely data
According to an article published by McKinsey & Company in 2020, they listed the key trends driving growth in oncology – which also could be transferred to other specialties. The “five key trends drive growth in the oncology space: democratized innovation, increased importance of precision medicine, increasing attention to value, complex and rapidly changing treatment paradigms, and the importance of stakeholder engagement amidst intense competition.”
Focus on “increasing attention to value, complex and rapidly changing treatment paradigms” is imperative to a conversation about developing a clinically driven GPO contract. With the increasing number of approvals for treatment and payers limiting or restricting their coverage based on outcomes data, biopharmaceutical companies need to quickly establish their value in the marketplace.
What types of data do you need to analyze to be confident in creating your GPO contracts:
- the clinical efficacy data and safety data from clinical trials;
- patient outcomes such as reduced hospitalizations or improvements in patient’s quality of life;
- comparator studies and health economic data with costs and analytics beyond prescribing data that can illustrate the overall cost benefit;
- analytics which show the market dynamics and the barriers or challenges your product might face, including reimbursement issues
This data can all help to determine if your goals are attainable with the current market landscape.
Understanding what is attainable during a contract period involves collaboration to address the specific clinical benefits and outcomes. By bridging the gap with insightful data related to an improved patient experience, your biopharmaceutical company is armed to inform both payers and healthcare providers.
IntrinsiQ Specialty Solutions has mapped over four million unique patients in our proprietary process, using more than 250 business rules and over 350,000 unique weekly patients in order to refine the data by the current market landscape. The mapping uses data from inventory and infusion management systems, EMRs and other clinical data sets and pharmacy dispensing.
Our team will work with you to understand your business needs and create an analytics portfolio that delivers on those goals. To start a conversation about how we partner with your biopharmaceutical company, contact email us at analyticsales@intrinsiq.com.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.